Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.
Many athletes, ball players, fighters, and any athlete who could benefit from the therapeutic relief often supplement with Deca Durabolin. Such individuals commonly have no desire to build any new lean muscle mass, but the relief alone is invaluable. Further, such relief can be obtained by a very low dose. A slightly higher dose will provide relief, greatly enhance overall recovery, and enhance muscular endurance. When it comes to performance enhancement, most athletes will find this steroid is hard to beat. More importantly, the relief effects of Deca Durabolin are not masking or false; this anabolic steroid shares nothing in common with over the counter painkillers or prescription painkillers like opiates. Such painkillers only mask the pain, whereas Deca Durabolin can actually heal the body.